Astrazeneca (AZN) Enterprise Value (2016 - 2026)

Astrazeneca has reported Enterprise Value over the past 18 years, most recently at -$7.9 billion for Q1 2026.

For Q1 2026, Enterprise Value fell 47.55% year-over-year to -$7.9 billion; the TTM value through Mar 2026 reached -$7.9 billion, down 47.55%, while the annual FY2025 figure was -$6.2 billion, 391.38% down from the prior year.
Enterprise Value for Q1 2026 was -$7.9 billion at Astrazeneca, down from -$6.2 billion in the prior quarter.
Over five years, Enterprise Value peaked at -$1.3 billion in Q4 2024 and troughed at -$8.6 billion in Q3 2025.
A 5-year average of -$5.9 billion and a median of -$6.0 billion in 2023 define the central range for Enterprise Value.
Biggest five-year swings in Enterprise Value: surged 78.94% in 2024 and later crashed 391.38% in 2025.
Year by year, Enterprise Value stood at -$6.2 billion in 2022, then increased by 4.77% to -$6.0 billion in 2023, then surged by 78.94% to -$1.3 billion in 2024, then crashed by 391.38% to -$6.2 billion in 2025, then dropped by 28.16% to -$7.9 billion in 2026.
Business Quant data shows Enterprise Value for AZN at -$7.9 billion in Q1 2026, -$6.2 billion in Q4 2025, and -$8.6 billion in Q3 2025.

Peer Comparison